24.00 -0.28 (-1.15%)
After hours: 5:36PM EDT
|Bid||23.98 x 4000|
|Ask||24.68 x 1200|
|Day's Range||23.88 - 24.51|
|52 Week Range||13.42 - 25.31|
|Beta (3Y Monthly)||2.03|
|PE Ratio (TTM)||10.99|
|Earnings Date||Apr 30, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
Morgan Stanley has dropped its bearish stance on Exelixis, Inc. (NASDAQ: EXEL ), although the research firm hasn't gained enough confidence to recommend buying the drugmaker's stock. The Analyst Analyst ...
The company took a crash course in trying to set up a transbay ferry service to get employees from South San Francisco to its new headquarters in Alameda.
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The biotech sector is an interesting one to follow. Warning! GuruFocus has detected 2 Warning Sign with CELG. There has been quite a bit of chatter recently surrounding the potential acquisition of the company by Bristol-Myers Squibb (BMY).
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Exelixis, Inc. (NASDAQ:EXEL) due to its excellent fundamentals in more thanRead More...
Pfizer's (PFE) application for Bavencio in combination with Inlyta for the treatment of advanced RCC gets validated by EMA.
Exelixis Inc is a biotechnology company. Warning! GuruFocus has detected 2 Warning Sign with DVA. For the last quarter Exelixis Inc reported a revenue of $228.6 million, compared with the revenue of $120.1 million during the same period a year ago.
The company reports fourth-quarter earnings above analysts' forecasts amid strong revenue from collaboration agreements and royalty payments to distribute its drugs.
This is the last heavy week of fourth quarter reports from companies within the S&P 500, with some 60 names reporting during the week. Earnings growth has been better than expected to this point with year-over-year profit growth north of 16%. While not the 20%-plus we have seen over the past few quarters, it is solidly above the approximate 14% rise that was the consensus before fourth quarter results started to hit the wires.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 12) Abbott Laboratories (NYSE: ABT ) Amphastar Pharmaceuticals ...
On a per-share basis, the Alameda, California-based company said it had profit of $1.15. Earnings, adjusted for pretax gains, came to 37 cents per share. The results beat Wall Street expectations. The ...
Exelixis (EXEL) delivered earnings and revenue surprises of 48.00% and 16.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?